Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTX131 in relapsed or refractory solid tumors
NCT05795595Phase 1
Key facts
- Status
- Completed
- Start
- Mar 2023
- Primary completion
- Sep 2025
- Countries
- 1
- Sponsor
- CRISPR Therapeutics
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Drugs
- CTX131
- Conditions
- clear cell renal cell carcinoma (ccRCC)cervical carcinomaesophageal carcinomapancreatic adenocarcinoma (PDAC)malignant pleural mesothelioma (MPM)
01
Overview
Phase 1, open-label, single-arm trial of CTX131 in clear cell renal cell carcinoma (ccRCC), cervical carcinoma, esophageal carcinoma and 2 more, sponsored by CRISPR Therapeutics. Primary endpoints: Incidence of adverse events at 28 days and Objective response rate at 60 months. Started Mar 2023; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
CTX131
Administered by IV infusion following lymphodepleting chemotherapy.
03
Who it enrols
Adults with relapsed/refractory clear cell renal cell carcinoma, cervical carcinoma, pancreatic adenocarcinoma, esophageal carcinoma, or malignant pleural mesothelioma, ECOG 0-1, adequate organ function, and no prior anti-CD70 therapy.
04
Endpoints
Primary
Incidence of adverse events
Objective response rate
Beyond the preview
Go deeper on NCT05795595.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05795595.